Table 1.
Patient demographics and characteristics.
| Total | 168 | |
|---|---|---|
| Sex | Male (n, %) | 87 (51.8) |
| Female (n, %) | 81 (48.2) | |
| Age | Median (min/max) | 62 (3/92) |
| ECOG PS | 0 (n, %) | 131 (78.0) |
| 1 (n, %) | 32 (19.0) | |
| 2 (n, %) | 5 (3.0) | |
| No. of previous chemotherapy lines | Median (min/max) | 3 (1/11) |
| Referral to our hospital for NGS assay | Yes, n (%) | 75(44.6) |
| No, n (%) | 93(55.4) | |
| Tissue of Origin | Primary site (n, %) | 111 (66.0) |
| Metastatic site (n, %) | 57 (34.0) | |
| Turnaround Time | Average (min/max) | 43 (35/51) |
| Cancer Type | Colorectal | 45 (26.8) |
| Sarcoma | 22 (13.0) | |
| Pancreatic | 18 (10.7) | |
| Gastric | 13 (7.7) | |
| Ovarian | 11 (6.5) | |
| Bile duct | 9 (5.4) | |
| Esophageal | 8 (4.8) | |
| Breast | 7 (4.2) | |
| Cervical | 6 (3.6) | |
| Small Intestinal | 5 (3.0) | |
| Hepatocellular | 3 (1.8) | |
| Unknown Primary | 3 (1.8) | |
| Endometrial | 3 (1.8) | |
| Non-Small Cell Lung | 3 (1.8) | |
| Brain | 3 (1.8) | |
| Neuroblastoma | 3 (1.8) | |
| Melanoma | 3 (1.8) | |
| Kidney | 1 (0.6) | |
| Prostate | 1 (0.6) | |
| Urinary tract | 1 (0.6) |
NGS: next-generation sequencing; ECOG PS: Eastern Cooperative Oncology Group performance status.